Disclaimer: This work has been submitted by the International Society of Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP). All authors are participating as ISPE or ISoP members, and the views expressed do not necessarily represent positions of their government, institution, or corporation.
Article first published online: 1 MAY 2007
Copyright © 2007 Kelly et al. Reproduced with permission by John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 5, pages 581–587, May 2007
How to Cite
Kelly, W. N., Arellano, F. M., Barnes, J., Bergman, U., Edwards, I. R., Fernandez, A. M., Freedman, S. B., Goldsmith, D. I., Huang, K., Jones, J. K., McLeay, R., Moore, N., Stather, R. H., Trenque, T., Troutman, W. G., van Puijenbroek, E., Williams, F. and Wise, R. P. (2007), Guidelines for submitting adverse event reports for publication. Pharmacoepidem. Drug Safe., 16: 581–587. doi: 10.1002/pds.1399
Conflicts of Interest: No sources of funding were used in preparing these guidelines and the authors have no conflicts of interest that are directly relevant to the content of these guidelines.
These Guidelines are published simultaneously in Drug Safety (2007; 30: 367–373).
- Issue published online: 1 MAY 2007
- Article first published online: 1 MAY 2007
- Manuscript Accepted: 26 FEB 2007
- 1Informativity of adverse reactions data in medical publications. Drug Inf J 1985; 19: 357–365..
- 5BMJ paper styles. Drug points http://bmj.bmjjournals.com/advice/sections.shtml. Accessed 2/9/05.
- 6Evaluation of published case reports' standards and notification. Drug Inf J 2002; 36: 303–307., , , et al.
- 16International Conference on Harmonisation. guidance on data elements for transmission of individual case safety reports; availability. Notice. Food and Drug Administration, HHS. Fed Regist 1998; 63: 2396–2404.